Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mylan, Natco and Novo Nordisk
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic,
Natco shares gain after antidiabetic drug partner Mylan, Novo Nordisk settle patent litigation
Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Natco Pharma soars after Mylan settles Ozempic patent dispute
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Natco Pharma settles US patent case over generic Ozempic
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Mylan and Novo Nordisk settle US generic Ozempic dispute, Natco Pharma poised for market entry
Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.
1d
on MSN
Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization ...
1d
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...
Daily
13d
Natco Pharma announces resignation of Sourav Chakraborty, Associate Vice President - Sales & Marketing, Crop Health Sciences Division
Telangana: Natco Pharma has announced that Sourav Chakraborty, Associate Vice President - Sales & Marketing, Crop Health ...
SUCH TV
2d
NATCO set to resume Gilgit-Kashgar bus service after 14-year hiatus
The Northern Areas Transport Corporation (NATCO) has officially received approval from the Federal Ministry of Communications ...
5h
L&T, Cochin Shipyard and 3 more: Axis Direct recommends buying these stocks for 5-15 days | Check targets, stop losses
Ahead of the market opening on Wednesday, Axis Direct picked five stocks that can generate profits in 5 to 15 days. These are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novo Nordisk
Mylan
Feedback